Gabelli Funds LLC bought a new position in shares of Bioverativ Inc (NASDAQ:BIVV) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 8,500 shares of the biotechnology company’s stock, valued at approximately $485,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Woodford Investment Management Ltd bought a new stake in Bioverativ during the 3rd quarter worth approximately $85,455,000. Old Mutual Global Investors UK Ltd. bought a new stake in Bioverativ during the 3rd quarter worth approximately $96,827,000. Frontier Capital Management Co. LLC bought a new stake in Bioverativ during the 3rd quarter worth approximately $54,653,000. First Trust Advisors LP bought a new stake in Bioverativ during the 3rd quarter worth approximately $38,238,000. Finally, First Quadrant L P CA bought a new stake in Bioverativ during the 3rd quarter worth approximately $19,310,000. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.watchlistnews.com/gabelli-funds-llc-buys-new-holdings-in-bioverativ-inc-bivv/1706853.html.

A number of equities research analysts have weighed in on BIVV shares. Zacks Investment Research raised shares of Bioverativ from a “hold” rating to a “strong-buy” rating and set a $73.00 target price on the stock in a report on Tuesday, July 25th. Cowen and Company reissued a “buy” rating and set a $80.00 target price on shares of Bioverativ in a report on Friday, August 4th. Royal Bank Of Canada initiated coverage on shares of Bioverativ in a report on Thursday, September 14th. They set a “sector perform” rating and a $59.00 target price on the stock. Evercore ISI initiated coverage on shares of Bioverativ in a research note on Wednesday, August 16th. They issued an “in-line” rating and a $58.00 price objective on the stock. Finally, Argus raised shares of Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price objective on the stock in a research note on Wednesday, September 20th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Bioverativ presently has a consensus rating of “Hold” and a consensus price target of $61.73.

Bioverativ Inc (BIVV) opened at $55.18 on Thursday. Bioverativ Inc has a 12 month low of $40.00 and a 12 month high of $64.41.

Bioverativ (NASDAQ:BIVV) last issued its earnings results on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.55 by $0.25. The business had revenue of $291.60 million for the quarter, compared to analyst estimates of $285.45 million. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The firm’s quarterly revenue was up 27.2% on a year-over-year basis. equities analysts anticipate that Bioverativ Inc will post 2.45 earnings per share for the current year.

Bioverativ Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Institutional Ownership by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.